Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Announces Earnings Results

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) posted its earnings results on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, FiscalAI reports.

Oaktree Acquisition Corp. III Life Sciences Stock Performance

Shares of OACC traded up $0.01 on Friday, hitting $10.71. 825 shares of the stock traded hands, compared to its average volume of 4,801. The stock’s 50 day moving average is $10.74 and its two-hundred day moving average is $10.70. Oaktree Acquisition Corp. III Life Sciences has a 1 year low of $10.50 and a 1 year high of $10.93.

Institutional Trading of Oaktree Acquisition Corp. III Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of OACC. Periscope Capital Inc. acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the 3rd quarter valued at $3,488,000. DLD Asset Management LP boosted its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% during the first quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Rangeley Capital LLC boosted its holdings in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% during the first quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock worth $647,000 after purchasing an additional 21,156 shares during the last quarter.

Analyst Ratings Changes

Separately, Weiss Ratings raised Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Hold rating. According to data from MarketBeat, Oaktree Acquisition Corp. III Life Sciences currently has a consensus rating of “Hold”.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to pursue a business combination with a company in the life sciences sector. Its potential transactions could include a merger, acquisition, or similar combination. The company was sponsored by Oaktree Capital Management. As a SPAC, it did not have its own operating business or sell products and services; its intended role was to identify and combine with a business in its target sector.